Adverse reactions : תופעות לוואי

6 ADVERSE REACTIONS
The following adverse reactions are discussed in greater detail in other sections of the labeling.
•   QT Interval Prolongation, PR Interval Prolongation [see Warnings and Precautions (5.4, 5.5)] •   Drug Interactions [see Warnings and Precautions (5.1)]
•   Pancreatitis [see Warnings and Precautions (5.2)]
•   Hepatotoxicity [see Warnings and Precautions (5.3)]


6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Adverse Reactions in Adults
The safety of KALETRA has been investigated in about 2,600 patients in Phase II-IV clinical trials, of which about 700 have received a dose of 800/200 mg (6 capsules or 4 tablets) once daily. Along with nucleoside reverse transcriptase inhibitors (NRTIs), in some studies, KALETRA was used in combination with efavirenz or nevirapine.
In clinical studies the incidence of diarrhea in patients treated with either KALETRA capsules or tablets was greater in those patients treated once daily than in those patients treated twice daily.
Any grade of diarrhea was reported by at least half of patients taking once daily Kaletra capsules or tablets.
At the time of treatment discontinuation, 4.2-6.3% of patients taking once daily Kaletra and 1.8-3.7% of those taking twice daily Kaletra reported ongoing diarrhea.
Commonly reported adverse reactions to KALETRA included diarrhea, nausea, vomiting, hypertriglyceridemia and hypercholesterolemia. Diarrhea, nausea and vomiting may occur at the beginning of the treatment while hypertriglyceridemia and hypercholesterolemia may occur later. The following have been identified as adverse reactions of moderate or severe intensity (Table 4): 

Table 4. Adverse Reactions of Moderate or Severe Intensity Occurring in at Least 0.1% of Adult Patients Receiving KALETRA in Combined Phase II/IV Studies (N=2,612)
System Organ Class (SOC) and Adverse Reaction                    n              % BLOOD AND LYMPHATIC SYSTEM DISORDERS anemia*                                                                     54              2.1 leukopenia and neutropenia*                                                 44              1.7 lymphadenopathy*                                                            35              1.3 CARDIAC DISORDERS atherosclerosis such as myocardial infarction*                              10              0.4 atrioventricular block*                                                      3              0.1 tricuspid valve incompetence*                                                3              0.1 EAR AND LABYRINTH DISORDERS vertigo*                                                                     7              0.3 tinnitus                                                                     6              0.2 ENDOCRINE DISORDERS hypogonadism*                                                               16             0.81 EYE DISORDERS


visual impairment*                                                   8    0.3 GASTROINTESTINAL DISORDERS diarrhea*                                                           510   19.5 nausea                                                              269   10.3 vomiting*                                                           177   6.8 abdominal pain (upper and lower)*                                   160   6.1 gastroenteritis and colitis*                                        66    2.5 dyspepsia                                                           53    2.0 pancreatitis*                                                       45    1.7 Gastroesophageal Reflux Disease (GERD)*                             40    1.5 hemorrhoids                                                         39    1.5 flatulence                                                          36    1.4 abdominal distension                                                34    1.3 constipation*                                                       26    1.0 stomatitis and oral ulcers*                                         24    0.9 duodenitis and gastritis*                                           20    0.8 gastrointestinal hemorrhage including rectal hemorrhage*            13    0.5 dry mouth                                                            9    0.3 gastrointestinal ulcer*                                              6    0.2 fecal incontinence                                                   5    0.2 GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS fatigue including asthenia*                                         198   7.6 HEPATOBILIARY DISORDERS hepatitis including AST, ALT, and GGT increases*                    91    3.5 hepatomegaly                                                         5    0.2 cholangitis                                                          3    0.1 hepatic steatosis                                                    3    0.1 IMMUNE SYSTEM DISORDERS hypersensitivity including urticaria and angioedema*                70    2.7 immune reconstitution syndrome                                       3    0.1 INFECTIONS AND INFESTATIONS upper respiratory tract infection*                                  363   13.9 lower respiratory tract infection*                                  202   7.7 skin infections including cellulitis, folliculitis, and furuncle*   86    3.3 METABOLISM AND NUTRITION DISORDERS

hypercholesterolemia*                                          192   7.4 hypertriglyceridemia*                                          161   6.2 weight decreased*                                              61    2.3 decreased appetite                                             52    2.0 blood glucose disorders including diabetes mellitus*           30    1.1 weight increased*                                              20    0.8 lactic acidosis*                                               11    0.4 increased appetite                                              5    0.2 MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS musculoskeletal pain including arthralgia and back pain*       166   6.4 myalgia*                                                       46    1.8 muscle disorders such as weakness and spasms*                  34    1.3 rhabdomyolysis*                                                18    0.7 osteonecrosis                                                   3    0.1 NERVOUS SYSTEM DISORDERS headache including migraine*                                   165   6.3 insomnia*                                                      99    3.8 neuropathy and peripheral neuropathy*                          51    2.0 dizziness*                                                     45    1.7 ageusia*                                                       19    0.7 convulsion*                                                     9    0.3 tremor*                                                         9    0.3 cerebral vascular event*                                        6    0.2 PSYCHIATRIC DISORDERS anxiety*                                                       101   3.9 abnormal dreams*                                               19    0.7 libido decreased                                               19    0.7 RENAL AND URINARY DISORDERS renal failure*                                                 31    1.2 hematuria*                                                     20    0.8 nephritis*                                                      3    0.1 REPRODUCTIVE SYSTEM AND BREAST DISORDERS erectile dysfunction*                                          34    1.71 menstrual disorders -amenorrhea, menorrhagia*                  10    1.72 SKIN AND SUBCUTANEOUS TISSUE DISORDERS

rash including maculopapular rash*                                        99            3.8 lipodystrophy acquired including facial wasting*                          58            2.2 dermatitis/rash including eczema and seborrheic dermatitis*               50            1.9 night sweats*                                                             42            1.6 pruritus*                                                                 29            1.1 alopecia                                                                  10            0.4 capillaritis and vasculitis*                                              3             0.1 VASCULAR DISORDERS hypertension*                                                             47            1.8 deep vein thrombosis*                                                     17            0.7 *Represents a medical concept including several similar MedDRA PTs
1. Percentage of male population (N=2,038)
2. Percentage of female population (N=574)


Laboratory Abnormalities in Adults
The percentages of adult patients treated with combination therapy with Grade 3-4 laboratory abnormalities are presented in Table 5 (treatment-naïve patients) and Table 6 (treatment-experienced patients).


Table 5. Grade 3-4 Laboratory Abnormalities Reported in ≥ 2% of Adult Antiretroviral-Naïve Patients
Study 863             Study 720            Study 730
(48 Weeks)               (360 Weeks)            (48 Weeks)
Variable             Limit1          KALETRA Nelfinavir              KALETRA        KALETRA KALETRA 400/100 mg       750 mg      Twice Daily + d4T Once Daily       Twice Twice Daily      Three            + 3TC           + TDF         Daily + + d4T +3TC Times Daily           (N = 100)        +FTC         TDF +FTC (N = 326)      + d4T +                          (N=333)        (N=331) 3TC
(N = 327)
Chemistry            High
Glucose              > 250 mg/dL         2%             2%               4%             0%            <1% Uric Acid            > 12 mg/dL          2%             2%               5%             <1%            1% SGOT/                > 180 U/L           2%             4%              10%             1%             2% AST2
SGPT/                >215 U/L            4%             4%              11%             1%             1% 
ALT2
GGT                >300 U/L             N/A             N/A              10%            N/A            N/A Total              >300 mg/dL            9%              5%              27%             4%            3% Cholesterol
Triglycerides      >750 mg/dL            9%              1%              29%             3%            6% Amylase            >2 x ULN              3%              2%              4%             N/A            N/A Lipase             >2 x ULN             N/A             N/A              N/A             3%            5% Chemistry          Low
Calculated         <50 mL/min           N/A             N/A              N/A             2%            2% Creatinine
Clearance
Hematology         Low
Neutrophils        <0.75 x 109/L         1%              3%              5%              2%            1% 1 ULN = upper limit of the normal range; N/A = Not Applicable.
2 Criterion for Study 730 was >5x ULN (AST/ALT).


Table 6. Grade 3-4 Laboratory Abnormalities Reported in ≥ 2% of Adult Protease Inhibitor- Experienced Patients
Study 888        Study 9572 and             Study 802
(48 Weeks)              Study 7653                (48 Weeks)
(84-144 Weeks)
Variable        Limit1     KALETRA Investigator- KALETRA                  KALETRA             KALETRA 400/100 mg    Selected        Twice Daily +    800/200 mg     400/100 mg Twice Twice      Protease          NNRTI +        Once Daily       Daily +NRTIs Daily +     Inhibitor(s)          NRTIs        +NRTIs              (N=299) NVP +       + NVP +            (N = 127)      (N=300)
NRTIs        NRTIs
(N = 148)     (N = 140)
Chemistry       High
Glucose         >250           1%             2%               5%              2%                 2% mg/dL
Total Bilirubin >3.48          1%             3%               1%              1%                 1% mg/dL
SGOT/AST4       >180 U/L       5%          11%                 8%              3%                 2% 

SGPT/ALT4       >215 U/L       6%            13%               10%             2%                  2% GGT             >300 U/L       N/A           N/A               29%            N/A                 N/A Total           >300           20%           21%               39%             6%                  7% Cholesterol     mg/dL
Triglycerides >750             25%           21%               36%             5%                  6% mg/dL
Amylase         >2 x ULN       4%            8%                8%              4%                  4% Lipase          >2 x ULN       N/A           N/A               N/A             4%                  1% Creatine        >4 x ULN       N/A           N/A               N/A             4%                  5% Phosphokinase
Chemistry       Low
Calculated      <50            N/A           N/A               N/A             3%                  3% Creatinine      mL/min
Clearance
Inorganic       <1.5           1%            0%                2%              1%                 <1% Phosphorus      mg/dL
Hematology Low
Neutrophils     <0.75 x        1%            2%                4%              3%                  4% 109/L
Hemoglobin      <80 g/L        1%            1%                1%              1%                  2% 1 ULN = upper limit of the normal range; N/A = Not Applicable.
2 Includes clinical laboratory data from patients receiving 400/100 mg twice daily (n = 29) or 533/133 mg twice daily (n = 28) for 84 weeks. Patients received KALETRA in combination with NRTIs and efavirenz.
3 Includes clinical laboratory data from patients receiving 400/100 mg twice daily (n = 36) or 400/200 mg twice daily (n = 34) for 144 weeks. Patients received KALETRA in combination with NRTIs and nevirapine.
4 Criterion for Study 802 was >5x ULN (AST/ALT).



6.2 Postmarketing Experience
The following adverse reactions have been reported during postmarketing use of KALETRA. Because these reactions are reported voluntarily from a population of unknown size, it is not possible to reliably estimate their frequency or establish a causal relationship to KALETRA exposure.

Body as a Whole
Redistribution/accumulation of body fat has been reported [see Warnings and Precautions (5.9)].

Cardiovascular
Bradyarrhythmias. First–degree AV block, second-degree AV block, third-degree AV block, QTc interval prolongation, torsades (torsade) de pointes [see Warnings and Precautions (5.4, 5.5].

Renal and Urinary Disorders
Nephrolithiasis

Skin and Appendages
Toxic epidermal necrolysis (TEN), Stevens Johnson-syndrome and erythema multiforme.

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il